share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

SEC announcement ·  Feb 27 17:04
Summary by Moomoo AI
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more